Incyte conducts its first patient treatment in a phase III clinical trial of ruxolitinib cream treatment

Recently, Incyte(http:// announcedthat the first patient has been treated in the Phase III TRuE-V ClinicalTrial(http://project to evaluate the treatment of vitiligo in the ruxolitinib creamThe project included two Phase III studies of TRuE-V1 (NCT040524225) and TRuE-V2 (NCT0405773), conducted in adolescents and adults aged 12 and over, in each study Approximately 300 patients in the planned group were diagnosed with non-segmented vitiligo (non-segmental vitiligo, NSV) and in areas with pigment ation, with the aim of assessing the efficacy and safety of ruxolitinib creams as a single therapyAbout ruxolitinib
ruxolitinib cream is apatented(http://formulation of Incyte's selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor ruxolitinib, designed for local applicationsRuxolitinib creams are currently under phase III clinical development:for the treatment of patients with mild to moderate asymptomatic dermatitis (TRuE-AD), preliminary results are expected in the first half of 2020, andfor the treatment of adolescent and adult vitiligo (TRuE-V)Incyte has a global right to develop and commercialize ruxolitinib creams 　　Ruxolitinib has been approved in the United States for 3 values should be: treatment of patients with erythritosus (PV) deficiency or intolerance of carbaplady urination ; A third indication, approved by the FDA (http:// in May, is the first drug (http:// approved to treat an indication Jakafi is sold by Incyte in the U.S., and Novartis is sold under the Jakavi brand in markets outside the U.S